Company News: SuppreMol Employs Protagen Biomarkers in SLE Study

SuppreMol GmbH, a privately held biopharmaceutical company developing innovative therapeutics for the treatment of autoimmune diseases and allergies, and Protagen AG, a specialist in in-vitro diagnostics and GMP-compliant protein analysis, today announced a collaboration to identify therapy-related biomarkers in patients with Systemic Lupus Erythematosus (SLE).

SuppreMol will use the biomarkers for the rapid identification of autoantibody signatures in the serum of SLE patients enrolled in the current phase IIa study of its lead product SM101. Thereby, the company hopes to identify patients who are most likely to respond favorable to SM101. Since SLE is a disease with very diverse manifestations, the findings may also allow for the classification of patients into subgroups .

Financial details of the collaboration are not disclosed. The cooperation as well as SuppreMol’s phase IIa SLE study are supported by the German Federal Ministry for Education and Research (BMBF) as part of the Leading Edge Cluster m4.